Skip to main content
Top

Cancer Chemotherapy and Pharmacology

Issue 3/1999

Content (11 Articles)

ORIGINAL ARTICLE

Antitumor activity, distribution, and metabolism of 13-cis -retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice

Barbara A. Conley, Thomas S. Ramsland, Dorothy L. Sentz, Suhlan Wu, D. Marc Rosen, Megan Wollman, Julie L. Eiseman

ORIGINAL ARTICLE

Efficacy of suramin against human prostate carcinoma DU145 xenografts in nude mice

Dawn Church, Yunlei Zhang, Randall Rago, George Wilding

ORIGINAL ARTICLE

Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo

Guido Bocci, Romano Danesi, Umberto Benelli, Federico Innocenti, Antonello Di Paolo, Stefano Fogli, Mario Del Tacca

ORIGINAL ARTICLE

Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer

Neal J. Meropol, Daryl S. Sonnichsen, Martin J. Birkhofer, Irene Ferreira, Diane Noel

ORIGINAL ARTICLE

Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity

Pierre Nazeyrollas, Alain Prévost, Nathalie Baccard, Leslie Manot, Philippe Devillier, Hervé Millart

ORIGINAL ARTICLE

The antitumor efficacy of cytotoxic drugs is potentiated by treatment with PNU 145156E, a growth-factor-complexing molecule

Francesco Sola, L. Capolongo, Donatella Moneta, Paolo Ubezio, Maria Grandi

ORIGINAL ARTICLE

Intrathecal 5-fluoro-2′-deoxyuridine (FdUrd) for the treatment of solid tumor neoplastic meningitis: an in vivo study

Hidemitsu Nakagawa, Masanobu Yamada, Masakazu Fukushima, Kazuhiro Ikenaka

CLINICAL TRIAL REPORT

Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial

K. Alexopoulos, C. Kouroussis, N. Androulakis, E. Papadakis, M. Vaslamatzis, S. Kakolyris, G. Samelis, E. Patila, A. Vossos, E. Samantas, V. Georgoulias

SHORT COMMUNICATION

Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism

Dagmar Busse, Friedrich W. Busch, Eberhard Schweizer, Frank Bohnenstengel, Michel Eichelbaum, Peter Fischer, Kurt Schumacher, Walter E. Aulitzky, Heyo K. Kroemer

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine